MK-767. Kyorin/Banyu/Merck

Calkin, A.C.; Thomas, M.C.; Cooper, M.E.; Calkin, A.C; Thomas, M.C; Cooper, M.E

Home

>

Node

>

Subnode

MK-767. Kyorin/Banyu/Merck

Calkin, A.C.; Thomas, M.C.; Cooper, M.E.

Current Opinion in Investigational Drugs 4(4): 444-448

2003

ISSN/ISBN: 1472-4472

PMID: 12808885

Document Number: 561624

MK-767 (KRP-297, L-410198) is a peroxisome proliferator-activated receptor (PPAR) alpha and PPAR gamma agonist under development by Banyu, Kyorin and Merck for the potential treatment of diabetes. The compound is currently undergoing phase III trials in the US and phase I trials in Japan.